Description

Landos Biopharma, Inc. is a biopharmaceutical firm operating in the clinical stage, focused on the discovery and development of innovative oral therapies aimed at treating a range of autoimmune disorders. Their leading clinical-stage candidate, omilancor, is an oral, gut-specific therapeutic designed to modulate lanthionine synthetase C-like protein 2 (LANCL2) activity. It is currently being investigated for treating ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis. Another pipeline asset, NX-13, is also an oral therapeutic localized to the gut, targeting the NOD-like receptor X1 (NLRX1) pathway, a mitochondrial receptor involved in regulating inflammatory cytokine production, for UC and CD. Furthermore, LABP-104 is an oral, small-molecule LANCL2 agonist designed to be systemically bioavailable, with potential applications in systemic lupus erythematosus and rheumatoid arthritis (RA). Beyond these clinical programs, Landos maintains a robust preclinical pipeline, featuring several promising compounds: LABP-66, an oral small molecule, acts as a NOD-like pathway agonist and is being explored for multiple sclerosis and Alzheimer's disease. LABP-69 is an oral PLXDC2 agonist targeting diabetic nephropathy and RA. LABP-73, another oral small molecule, modulates the NLRX1 pathway for potential use in asthma and chronic obstructive pulmonary disease. And LABP-111, an oral small molecule LANCL2 pathway agonist, is under investigation for nonalcoholic steatohepatitis and type 1 diabetes. Established in 2017, the company's corporate headquarters are situated in Blacksburg, Virginia.